Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection of Zika Virus; Availability; Correction, 31783 [2017-14365]
Download as PDF
Federal Register / Vol. 82, No. 130 / Monday, July 10, 2017 / Notices
their presentation on or before July 12,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 13, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Philip Bautista
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
virus outbreak in the Americas. The
document was published with the
incorrect docket number. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT: Lisa
Granger, Office of Policy and Planning,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 32, Rm.
3330, Silver Spring, MD 20993–0002,
301–796–9115.
SUPPLEMENTARY INFORMATION: In the
Federal Register of Friday, June 30,
2017, in FR Doc. 2017–13720, on page
29866, the following correction is made:
1. On page 29866, in the first column,
in the headings section at the beginning
of the document, the docket number is
corrected to read ‘‘FDA–2016–N–1486’’.
Dated: June 29, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
AGENCY:
[FR Doc. 2017–14364 Filed 7–7–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–1486]
Authorizations of Emergency Use of In
Vitro Diagnostic Devices for Detection
of Zika Virus; Availability; Correction
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration is correcting a notice
entitled ‘‘Authorizations of Emergency
Use of In Vitro Diagnostic Devices for
Detection of Zika Virus; Availability’’
that appeared in the Federal Register of
June 30, 2017 (82 FR 29886). The
document announced the issuance of
two Emergency Use Authorizations for
in vitro diagnostic devices for detection
of the Zika virus in response to the Zika
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:08 Jul 07, 2017
Jkt 241001
[FR Doc. 2017–14365 Filed 7–7–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Composition and Methods for
Delivering Inhibitory Oligonucleotides
for the Treatment of Pancreatic Cancer
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
The National Institute on
Aging, an institute of the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an Exclusive
Patent License to practice the inventions
embodied in the U.S. Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to VeriLuce Therapeutics
(‘‘VLT’’) located in Toronto, ON,
Canada.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before July 25, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Surekha Vathyam, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
SUMMARY:
BILLING CODE 4164–01–P
AGENCY:
Dated: June 30, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
31783
business mail), Rockville, MD 20850–
9702 Telephone: (240) 276–5530;
Facsimile: (240) 276–5504 Email:
vathyams@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
• United States Provisional Patent
Application No. 61/045,088, filed April
15, 2008, titled ‘‘Composition and
methods for delivering inhibitory
oligonucleotides’’, [HHS Reference No.
E–051–2008/0–US–01], status: expired;
• International Patent Application
No. PCT/US2009/040607, filed April 15,
2009, titled ‘‘Composition and methods
for delivering inhibitory
oligonucleotides’’, [HHS Reference No.
E–051–2008/0–PCT–02], status:
converted;
• Canadian Patent Application No.
2,720,363, filed April 15, 2009, titled
‘‘Composition and methods for
delivering inhibitory oligonucleotides’’,
[HHS Reference No. E–051–2008/0–CA–
04], status: pending;
• United States Patent Application
No. 12/988,148, filed March 8, 2011,
titled ‘‘Compositions and methods for
delivering inhibitory oligonucleotides’’
[HHS Reference No. E–051–2008/0–US–
07], status: issued as Patent No.
8,703,921;
• United States Patent Application
No. 14/220,726, filed March 20, 2014,
titled ‘‘Compositions and Methods for
delivering inhibitory oligonucleotides’’
[HHS Reference No. E–051–2008/0–US–
08], status: issued as Patent No.
9,415,116; and
• United States Patent Application
No. 15,204,789, filed July 7, 2016, titled
‘‘Compositions and Methods for
delivering inhibitory oligonucleotides’’
[HHS Reference No. E–051–2008/0–US–
11], status: pending.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Treatment of pancreatic
cancer by targeting regulatory T cells
using complexes or fusion molecules
comprising inhibitory nucleic acids, a
nucleic acid binding moiety and a
targeting polypeptide, wherein the
targeting polypeptide contains either the
TARC/CCL17 or RANTES/CCL5 cell
surface receptor ligand.’’
Despite significant attractiveness of
anti-sense oligonucleotide technology,
its clinical application has been
precluded by a lack of methods for
targeted delivery and transduction of
primary immune cells in vivo. Novel
complexes and methods for delivering
E:\FR\FM\10JYN1.SGM
10JYN1
Agencies
[Federal Register Volume 82, Number 130 (Monday, July 10, 2017)]
[Notices]
[Page 31783]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14365]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-1486]
Authorizations of Emergency Use of In Vitro Diagnostic Devices
for Detection of Zika Virus; Availability; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a notice
entitled ``Authorizations of Emergency Use of In Vitro Diagnostic
Devices for Detection of Zika Virus; Availability'' that appeared in
the Federal Register of June 30, 2017 (82 FR 29886). The document
announced the issuance of two Emergency Use Authorizations for in vitro
diagnostic devices for detection of the Zika virus in response to the
Zika virus outbreak in the Americas. The document was published with
the incorrect docket number. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy and
Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.
SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, June 30,
2017, in FR Doc. 2017-13720, on page 29866, the following correction is
made:
1. On page 29866, in the first column, in the headings section at
the beginning of the document, the docket number is corrected to read
``FDA-2016-N-1486''.
Dated: June 30, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-14365 Filed 7-7-17; 8:45 am]
BILLING CODE 4164-01-P